235 related articles for article (PubMed ID: 34500493)
21. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic profile of plasma cell leukemia: a retrospective study in a reference cancer center in India and review of literature.
Tembhare PR; Subramanian PG; Sehgal K; Yajamanam B; Kumar A; Gadge V; Inamdar N; Gujral S
Indian J Pathol Microbiol; 2011; 54(2):294-8. PubMed ID: 21623077
[TBL] [Abstract][Full Text] [Related]
23. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
[TBL] [Abstract][Full Text] [Related]
24. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
25. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia.
Kraj M; Kopeć-Szlęzak J; Pogłód R; Kruk B
Leuk Res; 2011 Feb; 35(2):169-76. PubMed ID: 20553988
[TBL] [Abstract][Full Text] [Related]
26. A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia.
Sorigue M; Juncà J; Gassiot S; Millá F; Mate JL; Navarro JT
Cytometry B Clin Cytom; 2015 Jan; 88(1):69-73. PubMed ID: 24715427
[TBL] [Abstract][Full Text] [Related]
27. Plasma cell leukemia.
Albarracin F; Fonseca R
Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
[TBL] [Abstract][Full Text] [Related]
28. Plasma cell leukemia: a retrospective study of 10 cases.
Agarwal AD; Brahmbhatt BS; Parikh BP; Shah MJ
Indian J Cancer; 2014; 51(1):18-9. PubMed ID: 24947090
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
30. Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.
Draxler DF; Wutzlhofer LM; Slavka G; Hübl W; Ludwig H; Schreder M; Reynolds J; Willheim M
Indian J Hematol Blood Transfus; 2019 Oct; 35(4):673-682. PubMed ID: 31741619
[TBL] [Abstract][Full Text] [Related]
31. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
32. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
33. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
34. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
[TBL] [Abstract][Full Text] [Related]
35. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
Jelinek T; Bezdekova R; Zihala D; Sevcikova T; Anilkumar Sithara A; Pospisilova L; Sevcikova S; Polackova P; Stork M; Knechtova Z; Venglar O; Kapustova V; Popkova T; Muronova L; Chyra Z; Hrdinka M; Simicek M; Garcés JJ; Puig N; Cedena MT; Jurczyszyn A; Castillo JJ; Penka M; Radocha J; Mateos MV; San-Miguel JF; Paiva B; Pour L; Rihova L; Hajek R
J Clin Oncol; 2023 Mar; 41(7):1383-1392. PubMed ID: 36315921
[TBL] [Abstract][Full Text] [Related]
36. Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
Klimienė I; Radzevičius M; Matuzevičienė R; Sinkevič-Belliot K; Kučinskienė ZA; Pečeliūnas V
Int J Lab Hematol; 2021 Jun; 43(3):403-408. PubMed ID: 33185981
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients.
Morice WG; Kurtin PJ; Hodnefield JM; Shanafelt TD; Hoyer JD; Remstein ED; Hanson CA
Mayo Clin Proc; 2008 Jul; 83(7):776-85. PubMed ID: 18613994
[TBL] [Abstract][Full Text] [Related]
38. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood.
Jiang NG; Jin YM; Niu Q; Zeng TT; Su J; Zhu HL
Ann Hematol; 2013 Jan; 92(1):89-96. PubMed ID: 22992980
[TBL] [Abstract][Full Text] [Related]
40. Questions concerning plasma cell leukaemia.
Lortholary P; Casassus P; Eclache V
Nouv Rev Fr Hematol (1978); 1992; 34(3):225-31. PubMed ID: 1408733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
